Weizman AV, et al. - This trial entailed the characterization of the prevalence and clinical characteristics of anti-tumor necrosis factor (anti-TNF)-associated psoriasis in subjects with inflammatory bowel disease patients. Evidence was obtained with regard to anti-TNF-associated psoriasis that correlated with female gender, foregut disease location, and fistulizing and stricturing disease behavior.

Methods

• Between 2004 and 2016 researchers analyzed the medical records of patients with Crohn’s disease or ulcerative colitis treated with anti-TNF therapy at a single, tertiary IBD center.
• Patients developed psoriasis while on anti-TNF and underwent a comprehensive retrospective review of dermatologic features and changes in IBD treatment prompted by the development of psoriasis.

Results

• The incidence of psoriasis was found to be 10.7% (N = 72,676) among patients treated with anti-TNF (infliximab or adalimumab).
• As per the results, female gender (OR 1.88 [95% CI 1.12-3.17], p=0.017), stricturing or fistulizing Crohn’s disease (OR 1.83 [95% CI 1.04-3.21], p=0.036) and upper GI Crohn’s disease (OR 3.03 [95% CI 1.06-8.33], p=0.039) exhibited a connection with psoriasis development.
• It was disclosed that the median time to psoriasis onset was 569 days from initiation of anti-TNF, with eaarlier onset in patients who developed psoriasis on adalimumab vs infliximab (457 vs 790.5 days, p=0.008).
• Findings unveiled that in 15/72 (20.8%), cases, anti-TNF cessation was warranted due to psoriasis.
• Plaque psoriasis served as the most common type of psoriatic lesion (75%).
• Data also illustrated that topical corticosteroids were the most common treatment for psoriasis.